Get started
Author

Destin Carlisle

Observed name: D. Carlisle
OpenAlex ID: A5014644013
A phase I/ II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202 )
2021 · Peter M. Voorhees, Vera J. Suman, et al. · American Journal of Hematology · 24
PDF
Alliance A061202. a Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib Versus Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor Based Therapy: Phase I Results
2015 · Peter M. Voorhees, Flora Mulkey, et al. · Blood · 24
Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse
2024 · Peter Voorhees, Vera Suman, et al. · Blood Advances · 5
Solitary plasmacytoma of bone (SPB): Randomized phase III trial to evaluate treatment with adjuvant systemic treatment and zoledronic acid (ZA) versus zoledronic acid after definitive radiation treatment (Alliance A061402)
2026 · Douglas Sborov, Anuj Mahindra, et al. · Research Square
PDF
Alliance A022102: Randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA).
2023 · Haeseong Park, Susan Michelle Geyer, et al. · Journal of Clinical Oncology
P-282: Addition of ixazomib to pomalidomide-dexamethasone improves progression-free survival for myeloma patients progressing on frontline lenalidomide: results of the randomized alliance study A061202
2022 · Peter Voorhees, Vera Suman, et al. · Clinical Lymphoma Myeloma & Leukemia
P968: Addition of Ixazomib to Pomalidomide and Dexamethasone Improves Progression-free Survival for Multiple Myeloma Patients Progressing on Lenalidomide as Part of 1st Line Therapy: Alliance A061202
2022 · P. Voorhees, V. Suman, et al. · HemaSphere
Works count: 7
Citation count: 53
H-index: 3
I10-index: 2
Year
Topic
Type